Armonair Digihaler is a drug owned by Teva Pharmaceutical Industries Ltd. It is protected by 57 US drug patents filed from 2020 to 2024. Out of these, 49 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 22, 2041. Details of Armonair Digihaler's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US11266796 (Pediatric) | Inhalation device with integrated electronics |
Aug, 2041
(16 years from now) | Active |
| US11266796 | Inhalation device with integrated electronics |
Feb, 2041
(16 years from now) | Active |
|
US11173259 (Pediatric) | Drug delivery device with electronics and power management |
Jan, 2041
(16 years from now) | Active |
|
US11464923 (Pediatric) | Inhaler system |
Dec, 2040
(16 years from now) | Active |
|
US11439777 (Pediatric) | Drug delivery device with electronics |
Nov, 2040
(15 years from now) | Active |
| US11173259 | Drug delivery device with electronics and power management |
Jul, 2040
(15 years from now) | Active |
| US11464923 | Inhaler system |
Jun, 2040
(15 years from now) | Active |
| US11439777 | Drug delivery device with electronics |
May, 2040
(15 years from now) | Active |
|
US11344685 (Pediatric) | Drug delivery device with electronics |
Mar, 2040
(15 years from now) | Active |
|
US11969544 (Pediatric) | Inhalers and airflow adaptors therefor |
Feb, 2040
(15 years from now) | Active |
| US11344685 | Drug delivery device with electronics |
Sep, 2039
(14 years from now) | Active |
| US11969544 | Inhalers and airflow adaptors therefor |
Aug, 2039
(14 years from now) | Active |
|
US11000653 (Pediatric) | Inhaler |
Jun, 2039
(14 years from now) | Active |
|
US11357935 (Pediatric) | Drug delivery device with electronics |
Mar, 2039
(14 years from now) | Active |
| US11000653 | Inhaler |
Dec, 2038
(14 years from now) | Active |
| US11357935 | Drug delivery device with electronics |
Sep, 2038
(13 years from now) | Active |
|
US11351317 (Pediatric) | Drug delivery device with electronics |
Aug, 2038
(13 years from now) | Active |
| US11351317 | Drug delivery device with electronics |
Feb, 2038
(13 years from now) | Active |
|
US10569034 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(12 years from now) | Active |
| US10569034 | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(11 years from now) | Active |
|
US10918816 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(11 years from now) | Active |
|
US9782551 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(11 years from now) | Active |
|
US9782550 (Pediatric) | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(11 years from now) | Active |
| US10918816 | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(10 years from now) | Active |
| US9782550 | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(10 years from now) | Active |
| US9782551 | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(10 years from now) | Active |
|
US8714149 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler |
May, 2031
(6 years from now) | Active |
|
US8978966 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(7 years from now) | Active |
|
US10561808 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(7 years from now) | Active |
| US8714149 | Airflow adaptor for a breath-actuated dry powder inhaler |
Nov, 2030
(5 years from now) | Active |
| US8978966 | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | Active |
| US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | Active |
|
US9216260 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | Active |
|
US10124131 (Pediatric) | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(6 years from now) | Active |
|
US9731087 (Pediatric) | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(6 years from now) | Active |
|
US10022510 (Pediatric) | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(6 years from now) | Active |
|
US10195375 (Pediatric) | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(6 years from now) | Active |
| US9216260 | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | Active |
| US9731087 | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | Active |
| US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | Active |
| US10124131 | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | Active |
| US10195375 | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | Active |
|
US8651103 (Pediatric) | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) | Active |
| US8651103 | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | Active |
|
US9463288 (Pediatric) | Dry powder inhalation apparatus |
Nov, 2025
(10 months from now) | Active |
|
US10765820 (Pediatric) | Dry powder inhalation apparatus |
Nov, 2025
(10 months from now) | Active |
| US9463288 | Dry powder inhalation apparatus |
May, 2025
(4 months from now) | Active |
| US10765820 | Dry powder inhalation apparatus |
May, 2025
(4 months from now) | Active |
|
US9616024 (Pediatric) | Process for preparing a medicament |
Mar, 2025
(2 months from now) | Active |
| US9616024 | Process for preparing a medicament |
Sep, 2024
(3 months ago) |
Expired
|
|
US7540282 (Pediatric) | Reservoir pressure system for medicament inhaler |
Nov, 2023
(1 year, 1 month ago) |
Expired
|
| US7540282 | Reservoir pressure system for medicament inhaler |
May, 2023
(1 year, 7 months ago) |
Expired
|
| US8006690 | Reservoir pressure system for medicament inhaler |
Jun, 2021
(3 years ago) |
Expired
|
| US6701917 | Dose counter for medicament inhaler |
Jun, 2021
(3 years ago) |
Expired
|
| US6871646 | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(3 years ago) |
Expired
|
| US6748947 | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(3 years ago) |
Expired
|
| US6718972 | Dose metering system for medicament inhaler |
Jun, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Armonair Digihaler's patents.
Latest Legal Activities on Armonair Digihaler's Patents
Given below is the list of recent legal activities going on the following patents of Armonair Digihaler.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2024 | US9463288 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765820 |
| Expire Patent Critical | 02 Oct, 2023 | US8006690 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jul, 2023 | US10561808 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jul, 2023 | US10569034 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 May, 2023 | US9216260 |
| Maintenance Fee Reminder Mailed Critical | 19 Apr, 2023 | US8006690 |
| Recordation of Patent Grant Mailed Critical | 11 Oct, 2022 | US11464923 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Oct, 2022 | US11464923 |
| Email Notification Critical | 22 Sep, 2022 | US11464923 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Armonair Digihaler and ongoing litigations to help you estimate the early arrival of Armonair Digihaler generic.
Armonair Digihaler's Litigations
Armonair Digihaler been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Armonair Digihaler's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10561808 | October, 2018 |
Decision
(20 Sep, 2019) | Declan Walsh et al. | |
FDA has granted some exclusivities to Armonair Digihaler. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Armonair Digihaler, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Armonair Digihaler.
Exclusivity Information
Armonair Digihaler holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Armonair Digihaler's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Several oppositions have been filed on Armonair Digihaler's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Armonair Digihaler's generic, the next section provides detailed information on ongoing and past EP oppositions related to Armonair Digihaler patents.
Armonair Digihaler's Oppositions Filed in EPO
Armonair Digihaler has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 03, 2009, by Vectura Delivery Devices Limited. This opposition was filed on patent number EP01948660A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP20172454A | Nov, 2022 | Vectura Limited | Granted and Under Opposition |
| EP19155324A | Jun, 2021 | Vectura Limited | Granted and Under Opposition |
| EP17811276A | Mar, 2021 | VECTURA DELIVERY DEVICES LIMITED | Opposition rejected |
| EP17800844A | Jun, 2020 | Vectura Limited | Opposition rejected |
| EP17800844A | Feb, 2020 | CHIESI FARMACEUTICI S.p.A. | Opposition rejected |
| EP04782768A | Apr, 2015 | AstraZeneca Pharma Poland Sp. z.o.o. | Revoked |
| EP01948660A | Aug, 2014 | Hexal Aktiengesellschaft | Patent maintained as amended |
| EP04782768A | Nov, 2011 | Vectura Limited | Revoked |
| EP04782768A | Nov, 2011 | AstraZeneca AB | Revoked |
| EP01948660A | Sep, 2009 | Vectura Delivery Devices Limited | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Armonair Digihaler is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Armonair Digihaler's family patents as well as insights into ongoing legal events on those patents.
Armonair Digihaler's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Armonair Digihaler's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Armonair Digihaler Generic API suppliers:
Fluticasone Propionate is the generic name for the brand Armonair Digihaler. 13 different companies have already filed for the generic of Armonair Digihaler, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Armonair Digihaler's generic
Alternative Brands for Armonair Digihaler
There are several other brand drugs using the same active ingredient (Fluticasone Propionate) as Armonair Digihaler. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fougera Pharms |
| ||||||||
| Glaxo Grp Ltd |
| ||||||||
| Mylan Speciality Lp |
| ||||||||
| Optinose Us Inc |
| ||||||||
| Teva Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluticasone Propionate, Armonair Digihaler's active ingredient. Check the complete list of approved generic manufacturers for Armonair Digihaler
About Armonair Digihaler
Armonair Digihaler is a drug owned by Teva Pharmaceutical Industries Ltd. Armonair Digihaler uses Fluticasone Propionate as an active ingredient. Armonair Digihaler was launched by Teva Pharm in 2022.
Approval Date:
Armonair Digihaler was approved by FDA for market use on 08 April, 2022.
Active Ingredient:
Armonair Digihaler uses Fluticasone Propionate as the active ingredient. Check out other Drugs and Companies using Fluticasone Propionate ingredient
Dosage:
Armonair Digihaler is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.113MG/INH | POWDER | Discontinued | INHALATION |
| 0.232MG/INH | POWDER | Discontinued | INHALATION |
| 0.055MG/INH | POWDER | Discontinued | INHALATION |
| 0.03MG/INH | POWDER | Discontinued | INHALATION |